Abstract：
UNASSIGNED: Bromocriptine is a dopamine receptor agonist used for central hyperthermia with limited data. We describe our single-center experience utilizing bromocriptine for central hyperthermia, including the population treated, most common dosing regimens, adverse events, and discontinuation reasons.
UNASSIGNED: A retrospective study was conducted screening patients who were admitted to intensive care units for acute neurological insults and administered bromocriptine for central hyperthermia between April 2016 and September 2022. Baseline characteristics, disease severity markers, and bromocriptine doses were collected. Body temperatures prior to the first dose of bromocriptine, at the time of dose, and after each dose were recorded. Co-administration of additional hyperthermia management therapies was noted.
UNASSIGNED: Thirty patients were included. The most common diagnosis was traumatic brain injury (TBI) (N = 14). The most common reason for discontinuation was resolution of indication (N = 14). Discontinuation due to mild adverse effects occurred in four patients; hepatotoxicity was the most common. There was a paired mean difference of -0.37°C (p = 0.005) between temperatures before and after bromocriptine initiation.
UNASSIGNED: Bromocriptine is a potential therapy for the management of central hyperthermia in patients with severe acute neurologic insults who have failed other therapies. Bromocriptine was well tolerated and associated with a low incidence of adverse events.
UNASSIGNED: A retrospective study was conducted screening patients who were admitted to intensive care units for acute neurological insults and administered bromocriptine for central hyperthermia between April 2016 and September 2022. Baseline characteristics, disease severity markers, and bromocriptine doses were collected. Body temperatures prior to the first dose of bromocriptine, at the time of dose, and after each dose were recorded. Co-administration of additional hyperthermia management therapies was noted.
UNASSIGNED: Thirty patients were included. The most common diagnosis was traumatic brain injury (TBI) (N = 14). The most common reason for discontinuation was resolution of indication (N = 14). Discontinuation due to mild adverse effects occurred in four patients; hepatotoxicity was the most common. There was a paired mean difference of -0.37°C (p = 0.005) between temperatures before and after bromocriptine initiation.
UNASSIGNED: Bromocriptine is a potential therapy for the management of central hyperthermia in patients with severe acute neurologic insults who have failed other therapies. Bromocriptine was well tolerated and associated with a low incidence of adverse events.
摘要：
■溴隐亭是用于中枢高热的多巴胺受体激动剂，数据有限。我们描述了我们利用溴隐亭治疗中枢高热的单中心经验，包括接受治疗的人群，最常见的给药方案，不良事件,和停止的原因。
进行了一项回顾性研究，筛选了在2016年4月至2022年9月期间因急性神经损伤而入院的重症监护病房并给予溴隐亭治疗中枢高热的患者。基线特征，疾病严重程度标记，并收集溴隐亭剂量。第一剂溴隐亭之前的体温，在剂量的时候，并在每次剂量后进行记录。注意到共同施用额外的热疗管理疗法。
■纳入30例患者。最常见的诊断是创伤性脑损伤（TBI）（N=14）。停药的最常见原因是适应症的消退（N=14）。四名患者因轻度不良反应而停药；肝毒性是最常见的。溴隐亭开始之前和之后的温度之间存在-0.37°C（p=0.005）的成对平均差。
■溴隐亭是治疗其他治疗失败的严重急性神经损伤患者的中枢高热的潜在治疗方法。溴隐亭耐受性良好，且不良事件发生率低。
进行了一项回顾性研究，筛选了在2016年4月至2022年9月期间因急性神经损伤而入院的重症监护病房并给予溴隐亭治疗中枢高热的患者。基线特征，疾病严重程度标记，并收集溴隐亭剂量。第一剂溴隐亭之前的体温，在剂量的时候，并在每次剂量后进行记录。注意到共同施用额外的热疗管理疗法。
■纳入30例患者。最常见的诊断是创伤性脑损伤（TBI）（N=14）。停药的最常见原因是适应症的消退（N=14）。四名患者因轻度不良反应而停药；肝毒性是最常见的。溴隐亭开始之前和之后的温度之间存在-0.37°C（p=0.005）的成对平均差。
■溴隐亭是治疗其他治疗失败的严重急性神经损伤患者的中枢高热的潜在治疗方法。溴隐亭耐受性良好，且不良事件发生率低。
